Sea Crest Wealth Management, LLC Bei Gene, Ltd. Transaction History
Sea Crest Wealth Management, LLC
- $913 Million
- Q4 2025
A detailed history of Sea Crest Wealth Management, LLC transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Sea Crest Wealth Management, LLC holds 620 shares of BGNE stock, worth $140,560. This represents 0.02% of its overall portfolio holdings.
Number of Shares
620Holding current value
$140,560% of portfolio
0.02%Shares
1 transactions
Others Institutions Holding BGNE
# of Institutions
296Shares Held
30.4MCall Options Held
147KPut Options Held
195K-
Baker Bros. Advisors LP New York, NY8.8MShares$1.99 Billion16.25% of portfolio
-
Primecap Management CO Pasadena, CA5.08MShares$1.15 Billion0.91% of portfolio
-
Capital International Investors Los Angeles, CA5.05MShares$1.14 Billion0.19% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.63MShares$370 Million0.06% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E91.03MShares$234 Million7.05% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $23.5B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...